Brief: Alligator And Aptevo To Initiate Phase I Clinical Development

Alligator Bioscience AB

16/11/2020 13:08

Nov 16 (Reuters) - Alligator Bioscience AB  ATORX.ST :
    * APTEVO THERAPEUTICS AND ALLIGATOR BIOSCIENCE ADVANCING THE
BISPECIFIC 4-1BBX5T4 ANTIBODY ALG.APV-527 INTO PHASE I CLINICAL
DEVELOPMENT
    * COMPANIES ANTICIPATE FILING A CLINICAL TRIAL AUTHORIZATION
DURING FIRST HALF OF 2021 TO INITIATE PHASE I CLINICAL
DEVELOPMENT IN MULTIPLE SITES IN EUROPEAN UNION

Source text for Eikon:  ID:nWkr2FRX3P 
Further company coverage:  ATORX.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))